RSS | Login | Register

PROTOPIC

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare PROTOPIC to:

Generic Name for PROTOPIC

Tacrolimus 0.03%, 0.1%; oint.

Legal Classification:

Pharmacological Class for PROTOPIC

Immunomodulator.

Manufacturer of PROTOPIC

Astellas Pharma US, Inc.

Indications for PROTOPIC

Second-line therapy: for short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised patients when other topical therapies are inadvisable or ineffective.

Adults and Children:

<2 years: not recommended. 2–15 years: use 0.03% strength. ≥16 years: use either strength. Apply to affected areas twice daily. Do not occlude or apply to wet skin.

Warnings/Precautions for PROTOPIC

Clear infection at treatment site first if present. Netherton's syndrome, generalized erythroderma, malignant or pre-malignant skin conditions: not recommended. Varicella zoster. Herpes simplex. Eczema herpeticum. Consider discontinuing if lymphadenopathy of unknown etiology or acute infectious mononucleosis develops. Avoid sun, UV light. Reevaluate if no improvement after 6 weeks. Renal impairment. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for PROTOPIC

Caution with CYP3A4 inhibitors in widespread and/or erythrodermic disease.

Adverse Reactions for PROTOPIC

Local reactions (eg, burning, pruritus, rash, folliculitis, acne, tingling, hyperesthesia, cysts), headache, flu symptoms, sinusitis, alcohol intolerance, back pain, varicella or herpes zoster, dyspepsia, myalgia; rare: malignancy (eg, skin, lymphoma).

How is PROTOPIC supplied?

Oint—30g, 60g, 100g

Related Disease:

Atopic dermatitis

Dermatological conditions, miscellaneous

Asclera injection available for sclerotherapy

July 15, 2010

BioForm Medical has launched Asclera (polidocanol injection), a sclerotherapy treatment.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

FDA issues warning letters for fat eliminating products

April 07, 2010

The FDA has issued warning letters to six medical spas for making false or misleading statements on their websites about drugs they claim will eliminate fat in a procedure called "lipodissolve," or for otherwise misbranding lipodissolve products.

EvoLife products available for cancer patients undergoing chemotherapy and radiotherapy

March 31, 2010

EvoLife Laboratories has launched its product line of skin, oral, nail, hair, hygiene care for cancer patients undergoing chemotherapy and radiotherapy.

Asclera approved for treatment of varicose veins

March 31, 2010

The FDA has approved Asclera (polidocanol injection, from BioForm Medical) for the treatment of small types of abnormally swollen or twisted veins called varicose veins.